New Products In Brief
This article was originally published in The Gray Sheet
Executive Summary
BioSTAR PFO closure device: NMT Medical launches its BioSTAR bioabsorbable atrial implant July 25 in Canada and Europe. The firm believes there may be a connection between closing septal heart defects, such as patent foramen ovale, with the device and prevention of embolic stroke and transient ischemic attack. NMT Medical estimates the market size in Canada and Europe for the indications to be 250,000 annually. AGA Medical's non-bioabsorbable Amplatzer PFO closure device is also available outside the United States. Both firms have U.S. trials underway to gain stroke prevention indications, and trials in the United States and internationally for prevention of migraine...
You may also be interested in...
With Limited Near-Term PFO Closure Prospects In U.S., NMT Looks To Europe
NMT Medical is banking on strong market growth in Europe to counteract stagnant U.S. performance
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”